Optivia Inks Drug-Interaction Collaboration with FDA | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Optivia Biotechnology today said that it will collaborate with the US Food and Drug Administration on identifying potentially harmful drug-dietary supplement interactions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."